Business

Oramed stock slumps ~70% as diabetes drug fails phase 3 study


Oramed Pharmaceuticals’ (NASDAQ:ORMP) drug ORMD-0801 did not meet the main goal of improving blood sugar levels, compared to placebo, in patients …

Read more

Show More

Related Articles

Back to top button